Star Therapeutics key facts
- Developer of antibody-based therapeutics designed to treat serious and underserved diseases through novel biological pathways.
- It has raised $315.0M across 3 recorded rounds; the latest was Later Stage VC (Series D) ($125.0M) in Sep 2025.
- Notable investors include Viking Global Investors, RA Capital Management, OrbiMed, Qatar Investment Authority, Catalio Capital Management — 19 tracked in total.
- Star Therapeutics has filed 1 Form D with the SEC, most recently Oct 2025 ($125.0M sold to 21 investors).
- Status: Privately Held (backing).
Who backs Star Therapeutics
19+- ·The complete investor list: 19 names
- ·Watch Star Therapeutics: the Monday email on marks, rounds and moves
Star Therapeutics funding rounds
3 roundsHow much has Star Therapeutics raised?
Star Therapeutics has raised $315 million across 3 recorded rounds since 2022. The largest was a $90 million Series C in Sep 2023; the most recent was a $125 million Series D in Sep 2025.
Star Therapeutics has filed 1 Form D with the SEC, most recently in Oct 2025 ($125 million sold to 21 investors).
Star Therapeutics investors
19 investors are on record for Star Therapeutics, including Viking Global Investors, RA Capital Management, OrbiMed and Qatar Investment Authority. By type, the record holds 5 venture capital firms, 3 asset managers and 3 private equity firms. The Series D in Sep 2025 drew 17 investors.
About Star Therapeutics
Developer of antibody-based therapeutics designed to treat serious and underserved diseases through novel biological pathways. The company offers a pipeline-in-a-product approach with proprietary antibody platforms, enabling patients with bleeding disorders to benefit from targeted, effective, and patient-centered treatments.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2018
- Employees
- 44
- Website
- star-therapeutics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Star Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.